Oncotelic Therapeutics, Inc. (OTLC) SEC Filing 8-K Material Event for the period ending Tuesday, July 12, 2022

Oncotelic Therapeutics, Inc.

CIK: 908259 Ticker: OTLC

View differences made from one to another to evaluate Oncotelic Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncotelic Therapeutics, Inc..


Assess how Oncotelic Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncotelic Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Oncotelic Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: OTLC
CIK: 908259
Form Type: 8-K Corporate News
Accession Number: 0001493152-22-019381
Submitted to the SEC: Fri Jul 15 2022 7:00:30 AM EST
Accepted by the SEC: Fri Jul 15 2022
Period: Tuesday, July 12, 2022
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: